Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Molecular Assays Developed for Hantavirus Pulmonary Syndrome

By LabMedica International staff writers
Posted on 16 Jan 2020
Hantavirus Pulmonary Syndrome (HPS) is a serious and often fatal disease caused by viruses known as hantaviruses. More...
These anthropozoonotic diseases comprising of two clinical entities: Hemorrhagic Fever with Renal Syndrome (HFRS), which occurs in the Old World, and Hantavirus Pulmonary Syndrome (HPS) in the New World.

Laboratory diagnosis of HPS is often conducted by enzyme-linked immunosorbent assay (ELISA) for detection of immunoglobulin G (IgG) and IgM specific antibodies in serum or blood of suspected patients. Given that IgM antibodies are detectable early in the disease, IgM ELISA is considered the reference method for HPS diagnostics.

Scientists at the Evandro Chagas Institute (Ananindeua, Brazil) have developed real-time polymerase chain reaction (RT-qPCR) and semi-nested RT-qPCR assays for the diagnosis of HPS. The assays were developed for detection and quantification of four hantaviruses strains circulating in the Brazilian Amazon. assays were used to test two groups of samples: one comprising of 50 patients with disease and other containing samples from 50 healthy individuals according to IgM-ELISA results. A third group of 27 samples infected with other pathogens were tested for specificity analysis.

A consensus region in the N gene of these hantaviruses was used to design the primer sets and a hydrolysis probe. In vitro transcribed RNA was diluted in standards with known concentration. MS2 bacteriophage RNA was detected together with hantavirus RNA as an exogenous control in a duplex reaction. RT-qPCR efficiency was around 100% and the limit of detection was 0.9 copies/μL of RNA for RT-qPCR and 10 copies/μL of RNA for Semi-nested RT-PCR. There was no amplification of either negative samples or samples positive to other pathogens. Sample reactions were performed in triplicate in ViiA7 qPCR System (Applied Biosystems, Thermo-Fisher Scientific, Waltham, MA, USA).

The investigators reported that the RT-qPCR was more sensitive than semi-nested RT-PCR, being able to detect three samples undetected by conventional RT-PCR. RT-qPCR clinical sensitivity, specificity and general accuracy values were 92.5%, 100% and 97.63%, respectively. Taken together, these results indicate that both RT-qPCR and Semi-nested RT-PCR assays are efficient, sensitive and specific tools for genome detection of hantaviruses circulating in the Amazon region. In addition to being more sensitive, RT-qPCR offers other advantages such as agility in generating results, about three times faster than conventional assays and automation capability which leads to lower risk of contamination and greater reproducibility. The study was published on December 26, 2019 in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Evandro Chagas Institute
Applied Biosystems



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.